NCT04447092View on ClinicalTrials.gov

Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

July 1, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Pancreatic CancerChemotherapy Effect
Interventions
DRUG

Gemcitabine

Gemcitabine 1000 mg/m2 iv D1, 8, 15 (every 4 weeks)

DRUG

Nab-paclitaxel

Nab-paclitaxel 125 mg/m2 iv D1, 8, 15 (every 4 weeks)

DRUG

Pembrolizumab

Pembrolizumab ( 200 ) mg iv D1 (every 3 weeks)

DRUG

Oxaliplatin

Oxaliplatin 65 mg/m2 iv over 2 hours D1 (every 2 weeks)

DRUG

Leucovorin

Leucovorin 400 mg/m2 iv D1 (every 2 weeks)

DRUG

Irinotecan

Irinotecan 140 mg/m2 iv over 1.5 hours D1 (every 2 weeks)

DRUG

5FU

5-FU 2400 mg/m2 iv over 46 hours D1 (every 2 weeks)

Trial Locations (1)

110-744

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER